Final Clinical Data Update from the NXP800 Ph 1b Study in Ovarian Cancer Provided and Completion of the NXP900 Ph 1a Dose Escalation Study Reported

Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, commented, “While the Phase 1b data provides evidence that NXP800 is biologically active in recurrent, platinum resistant, ARID1a-mutated ovarian cancer, we have decided to focus our near-term efforts on advancing NXP900.” Mr. Bentsur continued, “Recurrent, platinum resistant, ARID1a-mutated ovarian cancer is a rare and very difficult to treat disease with a dismal prognosis, so while any progress in improving outcomes for these patients is important, the time and resources that we believe will be required to further develop NXP800 in this disease setting led us to make this decision. We thank the investigators and study participants for their involvement in the NXP800 Phase 1b study.” Mr. Bentsur added, “That said, we believe that NXP800 is an active agent and in the coming months we will evaluate the feasibility of other opportunities in which NXP800 can potentially demonstrate its anti-cancer activity more profoundly.” Mr. Bentsur concluded, “We are excited to be at the cusp of initiating the Phase 1b program for NXP900, which will aim to unleash the significant therapeutic potential that we believe is embedded in NXP900.”